Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IGEN International -- Ignore unavailable to you. Want to Upgrade?

To: James Perry who wrote (325)	4/22/1998 1:57:00 AM
From: John Zwiener	Read Replies (1) \| Respond to of 1025

I have been checking on this Agouron news. And thinking. First, this confirms the good news with pfizer,,,that this is a top technology that is proving itself. Agouron is a classic situation where Igen's tech. has a major advantage. It is incredibly expensive for Agouron to do the kind of screening it must do. I don't think Agouron could afford to screen its entire library without Igen. As more companies get bigger in the intracellular enzymes, receptors, and ligands, etc,,, they will turn to Igen, IMO. An over billion dollar opportunity in a few years as this area of research grows exponentially. For example, a couple of years ago, there were only a dozen or two intercellular targets to work with. Now there are thousands, each which has a cellular function. Future medicines will be mainly in this area IMO. Because Aurora is getting 3% on it's deals on all future medicines discovered through it's process (and that is still 2 years away), I think Igen will seriously consider adding something like this in future deals. The Igen technology is in demand, and the first companies using it will have the advantage in identifying and patenting this emerging giant area of drug development. Igen is in a better position than aurora to get these deals, especially now that they have established credibility. The Agouron deal is probably relatively large, maybe we can get some idea from the next quarterly report, or subsequent ones. Since details are being withheld, we will have to look at revenues. I think the next report comes out around May 4, (at least last year it was around that). Will think some more. Igen will release production models of high thruput next year, in the meantime, we may get a reliable indication of what to expect from the alpha units of the high thruput, and the next generation regular thruput instruments. I am beginning to think Igen could be much bigger than even I had hoped, but need to wait for more confirmation. In the meantime, Igen is very underpriced, very. In my opinion, of course. You know James, I had fleeting thoughts, in the past, of Igen being one of the major medical/research instrument manufacturers and suppliers in the world.